Alexander M Gold sold $1.6M of MLYS
director at Mineralys Therapeutics, Inc.. 34,675 shares at an average of $45.45, traded Nov 11, 2025, filed Nov 13, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.6M at market
- +20Share of holdings soldSold 100% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001933414-25-000149, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2025 | MOption exercise Common Stock | +15,000 | $10.20 | $153k | 15,000 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Common Stock | -10,000 | $42.43 | $424k | 5,000 | Nov 13, 2025 |
| Nov 11, 2025 | SOpen-market sale Common Stock | -5,000 | $47.08 | $235k | 0 | Nov 13, 2025 |
| Nov 12, 2025 | MOption exercise Common Stock | +6,933 | $10.20 | $71k | 6,933 | Nov 13, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stock | -5,000 | $46.50 | $233k | 1,933 | Nov 13, 2025 |
| Nov 12, 2025 | SOpen-market sale Common Stock | -1,933 | $47.28 | $91k | 0 | Nov 13, 2025 |
| Nov 13, 2025 | MOption exercise Common Stock | +2,742 | $10.20 | $28k | 2,742 | Nov 13, 2025 |
| Nov 13, 2025 | MOption exercise Common Stock | +10,000 | $12.69 | $127k | 12,742 | Nov 13, 2025 |
| Nov 13, 2025 | SOpen-market sale Common Stock | -12,742 | $46.50 | $593k | 0 | Nov 13, 2025 |
| Nov 11, 2025 | MOption exercise Stock Optionderivative | -15,000 | $0.00 | $0 | 17,900 | Nov 13, 2025 |
| Nov 12, 2025 | MOption exercise Stock Optionderivative | -6,933 | $0.00 | $0 | 10,967 | Nov 13, 2025 |
| Nov 13, 2025 | MOption exercise Stock Optionderivative | -2,742 | $0.00 | $0 | 8,225 | Nov 13, 2025 |
| Nov 13, 2025 | MOption exercise Stock Optionderivative | -10,000 | $0.00 | $0 | 34,000 | Nov 13, 2025 |
Related signals
Other insiders at Mineralys Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | Mineralys Therapeutics, Inc. | Jon Congleton Chief Executive Officer | $1.9M 75,000 shares | -12% | |
| 55Moderate | Mineralys Therapeutics, Inc. | Brian Taylor Slingsby director | $3.0M 104,320 shares | -1% | |
| 12Weak | Mineralys Therapeutics, Inc. | Eric Warren Chief Commercial Officer | $209k 7,438 shares | -16% | |
| 14Weak | Mineralys Therapeutics, Inc. | Daphne Karydas director | $86k 3,000 shares | -33% | |
| 46Moderate | MLYSbuy Mineralys Therapeutics, Inc. | Ra Capital Management, L.p. director | $8.8M 369,000 shares | +7% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $11k 417 shares | -1% | |
| 4Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $543k 20,406 shares | -23% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $58k 2,171 shares | -3% | |
| 0Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $12k 417 shares | -1% | |
| 9Weak | Mineralys Therapeutics, Inc. | David Malcom Rodman Chief Medical Officer | $570k 20,404 shares | -36% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.